Jiangsu Hengrui Pharmaceuticals Co.,Ltd (JHPCY)

Market Cap	50.22B +18.2%
Revenue (ttm)	4.72B +11.6%
Net Income	1.18B +18.7%
EPS	0.18 +11.8%
Shares Out	n/a
PE Ratio	42.66
Forward PE	34.45
Dividend	0.04 (0.23%)
Ex-Dividend Date	Apr 30, 2026

Volume	100
Average Volume	330
Open	18.00
Previous Close	n/a
Day's Range	18.00 - 18.00
52-Week Range	16.72 - 18.00
Beta	n/a
RSI	n/a
Earnings Date	Aug 20, 2026

About JHPCY

Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.

• Industry: Pharmaceutical Preparations
• Founded: 1970
• Employees: 20,602
• Stock Exchange: OTCMKTS
• Ticker Symbol: JHPCY

Financial Performance

In 2025, JHPCY's revenue was 31.63 billion, an increase of 13.02% compared to the previous year's 27.98 billion. Earnings were 7.71 billion, an increase of 21.69%.

Financial numbers in CNY